olfactory receptor family 7 subfamily E member 66 pseudogeneGenealiases: OR3.3 · OR3DG · OR7E20P · OR7E6P · hg630
Q-omics provides the consensus-scored OR7E66P profile across patient tissues and cancer cell-line models. OR7E66P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, OR7E66P is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, OR7E66P RNA expression shows 6,183 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, ESCA, and TGCT as cancer lineages where OR7E66P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E66P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E66P survival associations across molecular data types. OR7E66P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E66P RNA expression–survival associations across cancer types. High OR7E66P expression shows unfavorable associations in UCEC, DLBC, PAAD, STAD and BRCA, but favorable associations in BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for OR7E66P RNA expression.
This table summarizes OR7E66P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E66P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E66P shows higher tumor expression in ESCA and STAD. The ESCA box plot shows higher OR7E66P RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .026).
This table shows molecular features associated with OR7E66P in patient tissues and cancer cell lines. In patient samples, OR7E66P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
